Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
John W. Childs, a director at Biohaven Ltd. (NYSE:BHVN), has recently increased his stake in the company by acquiring a substantial number of common shares. According to a recent SEC filing, Childs purchased a total of 32,700 shares on March 4, 2025. The shares were acquired at prices ranging from $30.3859 to $30.7261, resulting in a total transaction value of approximately $996,238. The timing is notable as the stock has experienced a significant 15.6% decline over the past week, according to InvestingPro data.
The acquisitions were made through various trusts, including the John W. Childs 2013 Revocable Trust, the 2007 Charitable Remainder Trust, the 2013 Charitable Remainder Trust, and the 1994 Charitable Remainder Trust. Following these transactions, the total number of shares owned by Childs across different trusts stands at over 4 million. With analyst price targets ranging from $54 to $77, significantly above the current trading price, and a strong cash position relative to debt, this insider purchase aligns with positive long-term indicators identified by InvestingPro.
These transactions reflect Childs’ continued confidence in Biohaven, a pharmaceutical company known for its innovative treatments in the life sciences sector. For deeper insights into BHVN’s valuation and growth prospects, including 12 additional ProTips, visit InvestingPro.
In other recent news, Biohaven Pharmaceutical (TADAWUL:2070) Holding has been the focus of several analyst reports, primarily highlighting its earnings and clinical program updates. Jefferies recently adjusted its price target for Biohaven from $64 to $63, maintaining a Buy rating despite mixed results in its latest earnings report. The firm noted positive developments in the BHV-1300 program, with an 80% median reduction in IgG levels, although concerns were raised about the 1000mg dose. TD Cowen also reaffirmed a Buy rating with a $75 target, praising the significant progress in the BHV-1300 program and the upcoming Phase II trial for Graves’ disease. RBC Capital maintained an Outperform rating with a $61 target, emphasizing the potential of Biohaven’s pipeline despite recent trial setbacks. Bernstein adjusted its price target to $57 from $73, citing challenges in the degrader platform and potential cash needs, but still recommends the stock as Outperform. Piper Sandler kept its Overweight rating with a $76 target, highlighting the positive data from the BHV-1300 trials and upcoming catalysts, despite the Phase 3 trial miss for BHV-7000 in bipolar disorder. These recent developments reflect ongoing optimism and challenges in Biohaven’s drug development pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.